SCHEMBL491209

SCHEMBL491209

CC(C)N(CC(=O)OC(C)(C)C)CC(C)(CN(CC(=O)OC(C)(C)C)C(C)C)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.33
CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4338603 0.76 CYP2D6 (0.34) CYP2D6
SCHEMBL7562972 0.74 CYP2D6 (0.41) CYP2D6CTSK
SCHEMBL7563852 0.72 CYP2D6 (0.34) CYP2D6
SCHEMBL5577164 0.72 CYP2D6 (0.39) CYP2D6CTSK
SCHEMBL13377425 0.72 DGAT1 (0.33) CYP2D6CTSK
SCHEMBL13981283 0.71 CYP2D6 (0.38) CYP2D6CTSK
SCHEMBL4347578 0.68 CYP2D6 (0.33) CYP2D6CTSK
SCHEMBL4332980 0.68 CYP2D6 (0.33) CYP2D6CTSK
SCHEMBL4332983 0.68 CYP2D6 (0.33) CYP2D6CTSK
SCHEMBL9001888 0.68 NR1D1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8105567-B2 Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy BRACCO IMAGING SPA (IT) 2012-01-31 US disclosed
EP-1803711-B1 Process for the preparation of multidentate aza ligands able to complex metal ions BRACCO IMAGING SPA (IT) 2011-10-19 EP disclosed
US-20110082280-A1 Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules BRACCO IMAGING S.P.A. (IT) 2011-04-07 US disclosed
US-7893223-B2 Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy BRACCO IMAGING S.P.A. (IT) 2011-02-22 US disclosed
US-20100069628-A1 Multidentate AZA Ligands Able to Complex Metal Ions And The Use Thereof In Diagnostics And Therapy BRACCO IMAGING S.P.A (IT) 2010-03-18 US disclosed
EP-1803711-A1 Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy BRACCO IMAGING S.p.A. (IT) 2007-07-04 EP disclosed
EP-1417183-B1 MULTIDENTATE AZA LIGANDS ABLE TO COMPLEX METAL IONS AND THE USE THEREOF IN DIAGNOSTICS AND THERAPY BRACCO IMAGING SPA (IT) 2007-05-23 EP disclosed
US-7186400-B2 Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy BRACCO IMAGING S.P.A. (IT) 2007-03-06 US disclosed
US-20060034773-A1 Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy BRACCO IMAGING SPA (IT) 2006-02-16 US disclosed
US-20040156786-A1 Multidentate aza ligands able to complex metal ions and the use therof in diagnostics and therapy BRACCO IMAGING S.P.A. (IT) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060034773-A1 Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy SSTR3, MB, CA13 CYP2D6 1494/4885CTSK 2358/4885
US-20110082280-A1 Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules CD99, CD209, PRMT9 CYP2D6 1550/4885CTSK 2509/4885
US-20040156786-A1 Multidentate aza ligands able to complex metal ions and the use therof in diagnostics and therapy SSTR1, SSTR3, TFRC CYP2D6 2217/4885CTSK 2701/4885
US-20100069628-A1 Multidentate AZA Ligands Able to Complex Metal Ions And The Use Thereof In Diagnostics And Therapy CD99, MB, HBZ CYP2D6 1685/4885CTSK 2510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.